- Home
- DTCX vs PLRX Comparison
DTCX vs PLRX Comparison
Compare DTCX & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DTCX | PLRX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 77.1M | 81.1M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DTCX | PLRX |
|---|---|---|
| Price | $2.27 | $1.30 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | ★ 596.1K | 502.8K |
| Earning Date | 05-22-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.51 | $1.09 |
| 52 Week High | $3.80 | $1.95 |
Technical Indicators
Market Signals| Indicator | DTCX | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 50.19 |
| Support Level | $1.70 | $1.12 |
| Resistance Level | $3.08 | $1.39 |
| Average True Range (ATR) | 0.35 | 0.07 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 19.19 | 64.58 |
Price Performance
Historical ComparisonAbout DTCX Datacentrex Inc. Common Stock
Datacentrex Inc maintains a digital asset treasury composed of assets generated through its mining hashrate, including Dogecoin (DOGE), Litecoin (LTC), and Bitcoin (BTC).
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.